| Time-resolved analysis reveals rapid dynamics and broad scope of the CBP/p300 acetylome BT Weinert, T Narita, S Satpathy, B Srinivasan, BK Hansen, C Schölz, ... Cell 174 (1), 231-244. e12, 2018 | 352 | 2018 |
| Inhibitors of human phosphatidylinositol 3-kinase delta C Sadhu, K Dick, J Treiberg, CG Sowell, EA Kesicki, A Oliver US Patent 6,518,277, 2003 | 213 | 2003 |
| Inhibitors of human phosphatidylinositol 3-kinase delta C Sadhu, K Dick, J Treiberg, CG Sowell, EA Kesicki, A Oliver US Patent 6,667,300, 2003 | 194 | 2003 |
| Inhibitors of human phosphatidylinositol 3-kinase delta C Sadhu, K Dick, J Treiberg, CG Sowell, EA Kesicki, A Oliver US Patent 6,800,620, 2004 | 192 | 2004 |
| Inhibitors of human phosphatidylinositol 3-kinase delta C Sadhu, KO Dick, J Treiberg, CG Sowell, EA Kesicki, A Oliver US Patent 8,138,195, 2012 | 180 | 2012 |
| Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta KW Fowler, D Huang, EA Kesicki, HC Ooi, A Oliver, F Ruan, J Treiberg US Patent 7,932,260, 2011 | 172 | 2011 |
| DNA-dependent protein kinase Is a molecular target for the development of noncytotoxic radiation–sensitizing drugs ET Shinohara, L Geng, J Tan, H Chen, YU Shir, E Edwards, J Halbrook, ... Cancer research 65 (12), 4987-4992, 2005 | 163 | 2005 |
| Inhibitors of human phosphatidyl-inositol 3-kinase delta C Sadhu, K Dick, J Treiberg, CG Sowell, EA Kesicki, A Oliver US Patent 6,949,535, 2005 | 152 | 2005 |
| DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer A Kashishian, H Douangpanya, D Clark, ST Schlachter, CT Eary, ... Molecular cancer therapeutics 2 (12), 1257-1264, 2003 | 147 | 2003 |
| Phenylboronic acid− salicylhydroxamic acid bioconjugates. 1. A novel boronic acid complex for protein immobilization ML Stolowitz, C Ahlem, KA Hughes, RJ Kaiser, EA Kesicki, G Li, KP Lund, ... Bioconjugate Chemistry 12 (2), 229-239, 2001 | 141 | 2001 |
| Validation of the essential ClpP protease in Mycobacterium tuberculosis as a novel drug target J Ollinger, T O'Malley, EA Kesicki, J Odingo, T Parish Journal of bacteriology 194 (3), 663-668, 2012 | 130 | 2012 |
| Synthesis and Postsynthetic Modification of Oligodeoxynucleotides Containing 4-Thio-2'-deoxyuridine (ds4U) RS Coleman, EA Kesicki Journal of the American Chemical Society 116 (26), 11636-11642, 1994 | 84 | 1994 |
| Materials and methods to potentiate cancer treatment J Halbrook, EA Kesicki, LE Burgess, ST Schlachter, CT Eary, JG Schiro, ... US Patent 7,179,912, 2007 | 75 | 2007 |
| A Novel Highly Stereoselective Synthesis of 2,3-Disubstituted 3H-Quinazoline-4-one Derivatives P Zhichkin, E Kesicki, J Treiberg, L Bourdon, M Ronsheim, HC Ooi, ... Organic Letters 9 (7), 1415-1418, 2007 | 70 | 2007 |
| A specific antagonist of the p110δ catalytic component of phosphatidylinositol 3′-kinase, IC486068, enhances radiation-induced tumor vascular destruction L Geng, J Tan, E Himmelfarb, A Schueneman, K Niermann, A Fu, ... Cancer research 64 (14), 4893-4899, 2004 | 68 | 2004 |
| Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta KW Fowler, D Huang, EA Kesicki, HC Ooi, A Oliver, F Ruan, J Treiberg US Patent 8,207,153, 2012 | 63 | 2012 |
| Synthesis and evaluation of the 2-aminothiazoles as anti-tubercular agents EA Kesicki, MA Bailey, Y Ovechkina, JV Early, T Alling, J Bowman, ... PLoS One 11 (5), e0155209, 2016 | 62 | 2016 |
| Discovery of spiro oxazolidinediones as selective, orally bioavailable inhibitors of p300/CBP histone acetyltransferases MR Michaelides, A Kluge, M Patane, JH Van Drie, C Wang, TM Hansen, ... ACS medicinal chemistry letters 9 (1), 28-33, 2018 | 61 | 2018 |
| Inhibitors of human phosphatidylinositol 3-kinase delta C Sadhu, K Dick, J Treiberg, CG Sowell, EA Kesicki, A Oliver US Patent 8,492,389, 2013 | 55 | 2013 |
| Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta KW Fowler, D Huang, EA Kesicki, HC Ooi, A Oliver, F Ruan, J Treiberg US Patent App. 12/732,124, 2010 | 55 | 2010 |
